Two Clinical Trials Indicate Tasimelteon May Help Establish Normal Sleep Rhythms For The Blind

By Dr Deepu

Reuters (8/12, Rapaport) reports that Vanda Pharmaceuticals Inc. announced that two clinical tests for Hetlioz (tasimelteon) showed that the drug helped blind patients achieve normal sleep rhythms. Last year, Hetlioz was approved by the Food and Drug Administration with orphan drug status, which allowed it to receive approval based upon smaller trials. The two studies examined 104 totally blind patients throughout 27 clinical trial centers in the US and Europe.